Abstract
This report highlights the case of a symptomatic 77-year-old non-smoking female patient who was diagnosed with advanced non-small-cell lung cancer (NSCLC), metastatic to the liver and contralateral lung. After tumor progression in the liver and lung following polychemotherapy, multiple diffuse brain and cerebellar metastases were apparent. Oral treatment with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’) 250 mg/day resulted in progressive and durable symptom relief, and improvements in quality of life and performance status. Reductions in the size of the primary pulmonary tumor and brain, cerebellar, and liver metastases were observed. Furthermore, gefitinib was well tolerated with an absence of adverse events. These results provide evidence that oral gefitinib is active in patients with advanced NSCLC and central nervous system metastases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vaporciyan AA, Nesbitt JC, Lee JS, Stevens CW, Komaki R, Roth JA: Cancer of the Lung. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei EI (eds) Cancer Medicine-5 Review. American Cancer Society and B.C. Decker Inc., pp 1227--1292, 2000
K Pavelic Z Banjac J Pavelic S Spaventi (1993) ArticleTitleEvidence for a role of EGF receptor in the progression of human lung carcinoma Anticancer Res 13 1133–1138 Occurrence Handle8394672
M Fukuoka S Yano G Giaccone T Tamura K Nakagawa J-Y Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova R-P Dong J Baselga (2003) ArticleTitleMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237–2246 Occurrence Handle10.1200/JCO.2003.10.038 Occurrence Handle12748244
MG Kris RB Natale RS Herbst TJ Lynch SuffixJr. D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay (2003) ArticleTitleEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial. JAMA 290 2149–2158
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s11060-005-2507-y.
Rights and permissions
About this article
Cite this article
Roggero, E., Giancarla, B., Antonella, P. et al. Gefitinib (‘Iressa’, ZD1839) is active against brain metastases in a 77 year old patient. J Neurooncol 71, 277–280 (2005). https://doi.org/10.1007/s11060-004-1719-x
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-1719-x